
Fate Therapeutics rose 31.6% from $0.97 to $1.28, ahead of the S&P 500's +11.2%. Its worst day was Nov 12 (−16.5%), and its low came Nov 17 at $0.97.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.27 beat the $-0.27 estimate on $1.4M revenue (est. $1.3M).
+5.4% · S&P 500 −0.6%
Story events cover the past 12 months · Times ET
Fate Therapeutics shares rose 31.1%, while the S&P 500 rose 0.8%.
+31.1%, the year's best day · S&P 500 +0.8%
EPS of $-0.26 beat the $-0.28 estimate on $1.3M revenue (est. $1.6M).
−5.1% · S&P 500 +0.6%
Fate Therapeutics shares rose 15.2%, while the S&P 500 rose 1.6%.
+15.2% · S&P 500 +1.6%
Fate Therapeutics closed at its highest level of the year, 219.6% above where the year started.
+6.1% · S&P 500 +0.8%
EPS of $-0.25 beat the $-0.26 estimate on $2.1M revenue (est. $1.2M).
−7.4% · S&P 500 +0.7%
EPS of $-0.25 beat the $-0.26 estimate on $0.00 revenue (est. $1.3M).
−11.5% · S&P 500 −4.4%
Where it ended: a close of $1.28 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.25, revenue est. $423,432.00).
Nothing in the past 12 months.
All FATE dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for FATE and SPY from Benzinga historical bars. Not investment advice.